Codeine Ultra-rapid Metabolizers: Age Appears to be a Key Factor in Adverse Effects of Codeine

Area of Science:

• Pharmacology
• Clinical Toxicology

Background:

• Codeine is a common analgesic with limited reported fatal adverse events in adults.
• Previous reports of severe reactions in neonates and children led to usage restrictions in pediatric populations.
• The safety profile of codeine in adults warrants specific investigation.

Purpose of the Study:

• To systematically review the safety of codeine in adult populations.
• To investigate the role of CYP2D6 genetic polymorphism in codeine-related adverse events in adults.
• To compare the incidence of adverse events in adults versus children.

Main Methods:

• Systematic literature search of PubMed for clinical studies and case reports on codeine safety in adults.
• Focus on cases involving serious or lethal effects, and the involvement of CYP2D6 enzyme activity.
• Analysis of contributing factors such as co-medication and intent of use (e.g., drug dependence, suicidal intent).

Main Results:

• 181 adult cases with serious or lethal codeine effects were identified, predominantly in drug-dependent individuals or with suicidal intent.
• Only two cases of severe non-lethal adverse events were linked to ultra-rapid CYP2D6 metabolizers.
• The incidence of severe adverse events in adults appears lower than predicted based on pediatric data, possibly due to developmental differences.

Conclusions:

• The existing regulatory restrictions on codeine use in infants and young children are supported by pharmacological and clinical evidence.
• The data suggest that codeine is relatively safe for adult use, with no apparent need for additional restrictions beyond those related to polypharmacy or intentional misuse.
• Developmental factors likely influence codeine metabolism and toxicity, explaining the observed differences between pediatric and adult populations.